Form 4: Supernus Pharmaceuticals SVP & CFO Timothy Dec Reports Stock Transactions

Timothy Dec, Senior Vice President & CFO of Supernus Pharmaceuticals, reports the acquisition of 2,500 shares and disposal of 1,314 shares of common stock on February 23, 2024, along with the disposal of 2,500 Restricted Stock Units.

Summary

• On February 23, 2024, Timothy C. Dec, the Senior Vice President & CFO of Supernus Pharmaceuticals, engaged in transactions involving the company's stock.
• Dec acquired 2,500 shares of common stock.
• Dec disposed of 1,314 shares of common stock to satisfy tax withholding requirements related to RSU vesting at a price of $29.06.
• Dec also disposed of 2,500 Restricted Stock Units (RSUs) which vest in four equal annual installments beginning on February 23, 2024.
• Following these transactions, Dec directly owns 7,190 shares of Supernus common stock and 7,500 Restricted Stock Units.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are routine and don't necessarily indicate a positive or negative outlook. The acquisition of shares is slightly positive, but the disposal for tax purposes is neutral.

Positives

• The acquisition of 2,500 shares could be interpreted as a positive signal, indicating confidence in the company's future performance.

Negatives

• The disposal of 1,314 shares to cover tax obligations is a standard practice and doesn't necessarily indicate a negative outlook.
• The disposal of 2,500 Restricted Stock Units (RSUs) is a standard practice and doesn't necessarily indicate a negative outlook.

Future Outlook

The RSUs vest in four equal annual installments, beginning on February 23, 2024, indicating a continued equity stake for the reporting person.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and confidence in the company.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, as insider transactions are often monitored for signals about the company's performance.

Key Dates